Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Biomedicine / Institutionen för biomedicin >
Doctoral Theses / Doktorsavhandlingar Institutionen för biomedicin >

Next Generation Sequencing for Measurable Residual Disease Detection in Acute Myeloid Leukemia

Please use this identifier to cite or link to this item:

Files in This Item:

File Description SizeFormat
gupea_2077_60780_1.pdfThesis frame6402KbAdobe PDF
gupea_2077_60780_4.pdfAbstract175KbAdobe PDF
gupea_2077_60780_8.pdfErrata56KbAdobe PDF
Title: Next Generation Sequencing for Measurable Residual Disease Detection in Acute Myeloid Leukemia
Authors: Delsing Malmberg, Erik
Issue Date: 30-Oct-2019
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Biomedicine. Department of Clinical Chemistry and Transfusion Medicine
Parts of work: I. Malmberg E. B.R., Ståhlman S., Rehammar A.,Samuelsson T., J. Alm S., Kristiansson E., Abrahamsson J., Garelius H., Pettersson L., Ehinger M., Palmqvist L. and Fogelstrand L. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing. European Journal of Haematology 2017 Jan;98(1):26-37.

II. Delsing Malmberg E., Rehammar A., Buongermino Pereira M., Abrahamsson J., Samuelsson T., Ståhlman S., Asp J., Tierens A., Palmqvist L., Kristiansson E., and Fogelstrand L. Accurate and sensitive analysis of minimal residual disease in acute myeloid leukemia using deep sequencing of single nucleotide variations. The Journal of Molecular Diagnostics 2019 Jan;21(1):149-162.

III. Delsing Malmberg E., J. Alm S., Nicklasson M., Lazarevic V., Ståhlman S., Samuelsson T., Lenhoff S., Asp J., Ehinger M., Palmqvist L., Brune M., and Fogelstrand L. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML. Leukemia & Lymphoma 2019 Feb;60(2):409-417.

IV. Løvvik Juul-Dam K.*, Delsing Malmberg E.*, Rehammar A., Kristiansson E., Abrahamsson J., Aggerholm A., Maria Dirdal M., Jahnukainen K., Lausen B., Beier Ommen H., Hasle H.† and Fogelstrand L.† Patient-tailored deep sequencing of blood enables early detection of relapse in childhood acute myeloid leukemia. *First authors contributed equally. † Senior authors contributed equally. Manuscript.
Date of Defence: 2019-11-29
Disputation: Fredagen den 29 november 2019, kl.9.00, Hörsal Karl Isaksson, Medicinaregatan 16A, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: acute myeloid leukemia
minimal residual disease
massively parallel sequencing
next generation sequencing
Abstract: Acute myeloid leukemia (AML) is the most common form of acute leukemia and generally associated with a poor prognosis. For both children and adults, the treatment is based on chemotherapy. Allogeneic hematopoietic stem cell transplant (alloHCT) is reserved for patients with intermediate or high risk of relapse, due to its associated risks. The initial response to treatment is a very important prognostic factor. The response is determined by the amount of residual leukemic cells in the bone marro... more
ISBN: 978-91-7833-462-9 (PRINT)
978-91-7833-463-6 (PDF)
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för biomedicin



© Göteborgs universitet 2011